Gulf War Illness Inflammation Reduction Trial
CompletedPhase 2NCT02506192
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes measures include changes from baseline levels of GWI-associated biomarkers of inflammation in peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and HRQOL with respect to mental functioning.
Study details
- Official title
- Gulf War Illness Inflammation Reduction Trial
- Conditions
- Chronic Inflammation
- Chronic Pain
- Fatigue
- Cognitive Impairment
- Interventions
- Drug: Modified-Release Prednisone
- Drug: Placebo
- Sponsor
- Minneapolis Veterans Affairs Medical Center
- Collaborators
- United States Department of Defense
- Start date
- 2015-07
- Primary completion
- 2023-10-19
- Sex
- All
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Scores moderate-severe on at least 3 out of 6 domains from the Kansas GWI Case Definition * Deployed, (and honorably discharged), from the Kuwaiti Theater of Operation (August 2, 1990-July 31, 1991) Exclusion Criteria: * Hospitalization anytime since 1990 for Alcohol or Drug Dependence, Depression, or PTSD * Known hypersensitivity to Prednisone * Liver, (active or recent Hepatitis B or C treatment with a completion date within the past 6 months, or alcohol liver disease), or Kidney Disease (Hep B and C ok if after 6 months of treatment) * Treated Diabetes * Females who are Pregnant or Nursing * Female who refuses to use an accepted method of birth control * Exclusionary Labs: C-Reactive Protein \>25, Creatinine Clearance \<30, EFGR ≥ 30, Hgb A1-C \>7, Glucose \>120, WBC \>12, RBC \>6.2, Hematocrit \>60, Hemoglobin \<11, Platelets \<100, Liver Function Tests (2 x the upper limit of AST and ALT, 2 x the upper limit of Total Bilirubin, and Alkaline Phosphatase) * Has Inflammatory Arthritis (RA, or Psoriatic Arthritis, Spondylitis, Polyarthritis) * Reactive Arthritis, or IBD associated Arthritis * Has any major inflammatory disease (acute Chronic Infections, Ulcerative Colitis, Crohn's Disease, Inflammatory lung diseases- COPD or Asthma requiring steroid treatment, Pericarditis, Vasculitis) * Has an chronic/active infection * Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable) * Active Gum Disease or Dental Infection * Has been diagnosed with Lupus, Stroke, or Multiple Sclerosis. or any other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition * Has a condition that may interfere with the ability to accurately report symptoms, (Severe Psychiatric Problems, Schizophrenia, Bipolar Disorder, Alcohol or Drug Dependence requiring hospitalization, or regular illegal drug use) * Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months * Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year. * Hospitalization within the past 3 months
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02506192